The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy

Michelle J. Pena, Dick de Zeeuw, Dennis Andress, John J. Brennan, Ricardo Correa-Rotter, Blai Coll, Donald E. Kohan, Hirofumi Makino, Vlado Perkovic, Giuseppe Remuzzi, Sheldon W. Tobe, Robert Toto, Hans Henrik Parving, Shoba Sharma, Tom Corringham, Kumar Sharma, Hiddo J L Heerspink

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We assessed the effect of atrasentan therapy on a pre-specified panel of 13 urinary metabolites known to reflect mitochondrial function in patients with diabetic kidney disease. This post-hoc analysis was performed using urine samples collected during the RADAR study which was a randomized, double-blind, placebo-controlled trial that tested the effects of atrasentan on albuminuria reduction in patients with type 2 diabetes and nephropathy. At baseline, 4 of the 13 metabolites, quantified by gas-chromatography mass spectrometry, were below detectable levels, and 6 were reduced in patients with eGFR<60mL/min/1.73m2. After 12weeks of atrasentan treatment in patients with eGFR<60mL/min/1.73m2, a single-value index of the metabolites changed by -0.31 (95%CI -0.60 to -0.02; P =.035), -0.08 (-12 to 0.29; P =.43) and 0.01 (-0.21 to 0.19; P =.913) in placebo, atrasentan 0.75 and 1.25mg/d, respectively. The metabolite index difference compared to placebo was 0.13 (-0.17 to 0.43; P =.40) and 0.35 (0.05-0.65; P =.02) for atrasentan 0.75 and 1.25mg/d, respectively. These data corroborate previous findings of mitochondrial dysfunction in patients with type 2 diabetes, nephropathy and eGFR<60mL/min/1.73m2, suggesting that atrasentan may prevent the progression of mitochondrial dysfunction common to this specific patient population. Future studies of longer treatment duration with atrasentan are indicated.

Original languageEnglish (US)
JournalDiabetes, Obesity and Metabolism
DOIs
StateAccepted/In press - 2017

Fingerprint

Type 2 Diabetes Mellitus
Placebos
Albuminuria
Diabetic Nephropathies
atrasentan
Gas Chromatography-Mass Spectrometry
Therapeutics
Urine
Population

Keywords

  • Diabetic kidney disease
  • eGFR decline
  • Metabolomics

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Pena, M. J., de Zeeuw, D., Andress, D., Brennan, J. J., Correa-Rotter, R., Coll, B., ... Heerspink, H. J. L. (Accepted/In press). The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12864

The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy. / Pena, Michelle J.; de Zeeuw, Dick; Andress, Dennis; Brennan, John J.; Correa-Rotter, Ricardo; Coll, Blai; Kohan, Donald E.; Makino, Hirofumi; Perkovic, Vlado; Remuzzi, Giuseppe; Tobe, Sheldon W.; Toto, Robert; Parving, Hans Henrik; Sharma, Shoba; Corringham, Tom; Sharma, Kumar; Heerspink, Hiddo J L.

In: Diabetes, Obesity and Metabolism, 2017.

Research output: Contribution to journalArticle

Pena, MJ, de Zeeuw, D, Andress, D, Brennan, JJ, Correa-Rotter, R, Coll, B, Kohan, DE, Makino, H, Perkovic, V, Remuzzi, G, Tobe, SW, Toto, R, Parving, HH, Sharma, S, Corringham, T, Sharma, K & Heerspink, HJL 2017, 'The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy', Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12864
Pena, Michelle J. ; de Zeeuw, Dick ; Andress, Dennis ; Brennan, John J. ; Correa-Rotter, Ricardo ; Coll, Blai ; Kohan, Donald E. ; Makino, Hirofumi ; Perkovic, Vlado ; Remuzzi, Giuseppe ; Tobe, Sheldon W. ; Toto, Robert ; Parving, Hans Henrik ; Sharma, Shoba ; Corringham, Tom ; Sharma, Kumar ; Heerspink, Hiddo J L. / The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy. In: Diabetes, Obesity and Metabolism. 2017.
@article{25fbeb6a136649deaed78c9a44ef87c9,
title = "The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy",
abstract = "We assessed the effect of atrasentan therapy on a pre-specified panel of 13 urinary metabolites known to reflect mitochondrial function in patients with diabetic kidney disease. This post-hoc analysis was performed using urine samples collected during the RADAR study which was a randomized, double-blind, placebo-controlled trial that tested the effects of atrasentan on albuminuria reduction in patients with type 2 diabetes and nephropathy. At baseline, 4 of the 13 metabolites, quantified by gas-chromatography mass spectrometry, were below detectable levels, and 6 were reduced in patients with eGFR<60mL/min/1.73m2. After 12weeks of atrasentan treatment in patients with eGFR<60mL/min/1.73m2, a single-value index of the metabolites changed by -0.31 (95{\%}CI -0.60 to -0.02; P =.035), -0.08 (-12 to 0.29; P =.43) and 0.01 (-0.21 to 0.19; P =.913) in placebo, atrasentan 0.75 and 1.25mg/d, respectively. The metabolite index difference compared to placebo was 0.13 (-0.17 to 0.43; P =.40) and 0.35 (0.05-0.65; P =.02) for atrasentan 0.75 and 1.25mg/d, respectively. These data corroborate previous findings of mitochondrial dysfunction in patients with type 2 diabetes, nephropathy and eGFR<60mL/min/1.73m2, suggesting that atrasentan may prevent the progression of mitochondrial dysfunction common to this specific patient population. Future studies of longer treatment duration with atrasentan are indicated.",
keywords = "Diabetic kidney disease, eGFR decline, Metabolomics",
author = "Pena, {Michelle J.} and {de Zeeuw}, Dick and Dennis Andress and Brennan, {John J.} and Ricardo Correa-Rotter and Blai Coll and Kohan, {Donald E.} and Hirofumi Makino and Vlado Perkovic and Giuseppe Remuzzi and Tobe, {Sheldon W.} and Robert Toto and Parving, {Hans Henrik} and Shoba Sharma and Tom Corringham and Kumar Sharma and Heerspink, {Hiddo J L}",
year = "2017",
doi = "10.1111/dom.12864",
language = "English (US)",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy

AU - Pena, Michelle J.

AU - de Zeeuw, Dick

AU - Andress, Dennis

AU - Brennan, John J.

AU - Correa-Rotter, Ricardo

AU - Coll, Blai

AU - Kohan, Donald E.

AU - Makino, Hirofumi

AU - Perkovic, Vlado

AU - Remuzzi, Giuseppe

AU - Tobe, Sheldon W.

AU - Toto, Robert

AU - Parving, Hans Henrik

AU - Sharma, Shoba

AU - Corringham, Tom

AU - Sharma, Kumar

AU - Heerspink, Hiddo J L

PY - 2017

Y1 - 2017

N2 - We assessed the effect of atrasentan therapy on a pre-specified panel of 13 urinary metabolites known to reflect mitochondrial function in patients with diabetic kidney disease. This post-hoc analysis was performed using urine samples collected during the RADAR study which was a randomized, double-blind, placebo-controlled trial that tested the effects of atrasentan on albuminuria reduction in patients with type 2 diabetes and nephropathy. At baseline, 4 of the 13 metabolites, quantified by gas-chromatography mass spectrometry, were below detectable levels, and 6 were reduced in patients with eGFR<60mL/min/1.73m2. After 12weeks of atrasentan treatment in patients with eGFR<60mL/min/1.73m2, a single-value index of the metabolites changed by -0.31 (95%CI -0.60 to -0.02; P =.035), -0.08 (-12 to 0.29; P =.43) and 0.01 (-0.21 to 0.19; P =.913) in placebo, atrasentan 0.75 and 1.25mg/d, respectively. The metabolite index difference compared to placebo was 0.13 (-0.17 to 0.43; P =.40) and 0.35 (0.05-0.65; P =.02) for atrasentan 0.75 and 1.25mg/d, respectively. These data corroborate previous findings of mitochondrial dysfunction in patients with type 2 diabetes, nephropathy and eGFR<60mL/min/1.73m2, suggesting that atrasentan may prevent the progression of mitochondrial dysfunction common to this specific patient population. Future studies of longer treatment duration with atrasentan are indicated.

AB - We assessed the effect of atrasentan therapy on a pre-specified panel of 13 urinary metabolites known to reflect mitochondrial function in patients with diabetic kidney disease. This post-hoc analysis was performed using urine samples collected during the RADAR study which was a randomized, double-blind, placebo-controlled trial that tested the effects of atrasentan on albuminuria reduction in patients with type 2 diabetes and nephropathy. At baseline, 4 of the 13 metabolites, quantified by gas-chromatography mass spectrometry, were below detectable levels, and 6 were reduced in patients with eGFR<60mL/min/1.73m2. After 12weeks of atrasentan treatment in patients with eGFR<60mL/min/1.73m2, a single-value index of the metabolites changed by -0.31 (95%CI -0.60 to -0.02; P =.035), -0.08 (-12 to 0.29; P =.43) and 0.01 (-0.21 to 0.19; P =.913) in placebo, atrasentan 0.75 and 1.25mg/d, respectively. The metabolite index difference compared to placebo was 0.13 (-0.17 to 0.43; P =.40) and 0.35 (0.05-0.65; P =.02) for atrasentan 0.75 and 1.25mg/d, respectively. These data corroborate previous findings of mitochondrial dysfunction in patients with type 2 diabetes, nephropathy and eGFR<60mL/min/1.73m2, suggesting that atrasentan may prevent the progression of mitochondrial dysfunction common to this specific patient population. Future studies of longer treatment duration with atrasentan are indicated.

KW - Diabetic kidney disease

KW - eGFR decline

KW - Metabolomics

UR - http://www.scopus.com/inward/record.url?scp=85013371547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013371547&partnerID=8YFLogxK

U2 - 10.1111/dom.12864

DO - 10.1111/dom.12864

M3 - Article

C2 - 28019071

AN - SCOPUS:85013371547

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

ER -